Oxford Biomedica appoints new CEO and Board Member
Oxford Biomedica has appointed Dr Frank Mathias has its new CEO, also joining the firm’s board.
Dr Frank joins from full-service CDMO Rentschler Biopharma, where he was the CEO, and brings experience in innovation, contract development and manufacturing.
Along with the appointment, the firm has announced two changes to its board. Stuart Henderson will become Vice Chair, a newly created position which replaces the previously combined role of Deputy Chair and Senior Independent Director which Stuart filled since June 2020.
Professor Dame Kay Davies will take on the role of Senior Independent Director, following her appointment as a Non-Executive Director in March 2021.
Read more - Oxford Biomedica celebrates agreements with three US companiesÂ
